Phase 4 N=386 The Study of Soy Isoflavones in Asthma
Asthma
Primary: Mean Change From Baseline to 24 Weeks for FEV1 — -0.001; 0.03 Liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=165 Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events (AEs) — 160; 7; 11; 15 participants
Phase 2 N=76 Vilazodone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS
Phase 2 N=44 Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: Median Progression Free Survival (PFS) — 3; 1.2 months — p=0.0001
N/A N=34 Neuropharmacological Basis of Social Connection: The Role of Opioids
Psychology, Social
Primary: Changes in Self-reported Feelings of Connection During Naltrexone (vs. Placebo) — 5.92; 6.47 units on a scale
Phase 1 N=48 Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets
Malaria
Primary: OZ439 Cmax — 1600; 824; 616; 1530 ng/mL
N/A N=28 "Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"
Light Sensitivity
Primary: Heart Rate — 154; 154; 152; 163 Beats per minutes
N/A N=212 Quantitative Automated Lesion Detection of Traumatic Brain Injury
Traumatic Brain Injury
Primary: Performance on Trail-making Test, Part B — -0.02; 0.18 z-score — p=< 0.04
Phase 2 N=18 A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
HIV Infections
Primary: Plasma Trough Concentrations (Ctrough) for Saquinavir — 645; 1860 ng/mL
Phase 2 N=12 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Recurrent Childhood Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 1 participants
Phase 2 N=15 Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers
Pressure Ulcer · Wound
Primary: Efficacy Index (%EI) — 82.76; 43.66; 14.58 percentage (%)
N/A N=184 Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants on TCZ Treatment at 6 Months After Treatment Initiation — 42.4 percentage of participants
Phase 3 N=834 Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Melanoma
Primary: Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology…
Phase 4 N=100 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM — 16.7; 15.4; 16.2; 15.6 Millimeters of Mercury (mmHg)
Phase 4 N=942 REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virological Response Rate — 52; 27 participants — p=0.0060